FDA advisory committee
FDA to Convene Meeting on New Ways to Increase Naloxone Availability
The FDA has announced a two-day advisory committee meeting to solicit input and advice on strategies to increase ...
NOVEMBER 6, 2018
FDA Committee Recommends Approval of Lofexidine for Opioid Withdrawal
In a nearly unanimous vote, an FDA committee recently recommended approval of lofexidine (Lucemyra, US WorldMeds), ...
APRIL 4, 2018
FDA Advisory Committee Fails to Recommend Approval of Hydexor
Coupled with concern over the opioid epidemic, the committee was not convinced that the product's efficacy in ...
FEBRUARY 15, 2018
Plivensia Rejected by FDA to Treat Rheumatoid Arthritis
The FDA Arthritis Advisory Committee has voted to deny the Biologics License Application approval of Johnson & ...
AUGUST 10, 2017
Amid Growing Health Concerns, FDA Recommends Opioid Pulled From Market
The FDA has asked Endo Pharmaceuticals to remove an opioid pain medication, reformulated extended-release ...
JUNE 9, 2017
FDA Joint Committee Votes Opana ER Risks Outweigh Benefits
Most of the panelists agreed that the drug should be removed from the market due to its high potential for IV ...
MARCH 29, 2017